AONN+ Conference Abstracts

Work is central for most adults in the United States, including women with breast cancer.

Cancer patients must juggle doctor appointments; combat treatment side effects, while trying to maintain a sense of normalcy; and handle financial struggles.

The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.

This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.

Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment breaks.

Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.

Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life.

In this special breast cancer issue of JONS, we are proud to present the 12 evidence-based breast cancer research abstracts that were presented as posters at the 2017 AONN+ Annual Conference.

This study was designed to identify changes in patient knowledge and anxiety levels following implementation of planned prechemotherapy education sessions.

We ask, “How can nurse navigators better educate disparate populations about breast health and cancer screening at home and abroad?”